Thermo Fisher Scientific Inc. $TMO Shares Bought by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Thermo Fisher Scientific by 3.3%, acquiring an additional 4,258 shares during the second quarter, bringing its total to 131,408 shares worth approximately $56.4 million.
• Wall Street analysts have mixed ratings for TMO stock; while Barclays upgraded it to an "overweight" rating with a target price of $550, Wall Street Zen and HSBC downgraded it to a "hold" rating.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, which will be paid on October 15th, representing an annualized dividend yield of 0.4%.

Wealth Enhancement Advisory Services LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,408 shares of the medical research company's stock after buying an additional 4,258 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $56,417,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares in the last quarter. Amundi increased its stake in shares of Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TMO shares. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Finally, Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $5.04 during mid-day trading on Monday, reaching $474.54. The company had a trading volume of 2,352,185 shares, compared to its average volume of 1,557,193. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock's 50-day simple moving average is $472.99 and its two-hundred day simple moving average is $448.55. The stock has a market capitalization of $179.19 billion, a P/E ratio of 27.45, a P/E/G ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.